AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.650
-0.060 (-2.21%)
Aug 28, 2026, 4:00 PM EDT - Market closed

AC Immune Revenue

AC Immune had revenue of 15.11M CHF in the quarter ending June 30, 2026, with 1,057.20% growth. This brings the company's revenue in the last twelve months to 17.51M, down -39.45% year-over-year. In the year 2025, AC Immune had annual revenue of 3.57M, down -86.92%.

Revenue (ttm)
17.51M CHF
Revenue Growth
-39.45%
P/S Ratio
12.16
Revenue / Employee
143,516 CHF
Employees
122
Market Cap
263.48M USD

Revenue Chart

* This company reports financials in CHF.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20253.57M-23.74M-86.92%
Dec 31, 202427.31M12.51M84.51%
Dec 31, 202314.80M10.87M276.14%
Dec 31, 20223.94M--
Dec 31, 2021---
Dec 31, 202015.43M-95.03M-86.03%
Dec 31, 2019110.46M103.54M1,498.03%
Dec 31, 20186.91M-13.34M-65.88%
Dec 31, 201720.26M-2.96M-12.75%
Dec 31, 201623.21M-15.88M-40.61%
Dec 31, 201539.09M8.82M29.14%
Dec 31, 201430.27M21.63M250.46%
Dec 31, 20138.64M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
MacroGenics175.14M
Niagen Bioscience129.08M
Cellectis63.82M
Alector13.86M
Surrozen11.51M
Pyxis Oncology11.04M
Whitehawk Therapeutics7.15M
Camp4 Therapeutics4.22M
Revenue Rankings